Physician profile
Britta Smith
NPI 1205352242
$1,492.83
in general payments reported to CMS, 2019-2025
21 companies · $728 in 2025
The $728 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $142 · 2024: $244 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $220.12 | 2023-2025 | Fintepla, Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $159.78 | 2022-2025 | Ultomiris |
| Argenx US, INC. | $147.23 | 2024-2025 | Vyvgart Hytrulo |
| Silk Road Medical, INC. | $129.26 | 2022 | |
| Novo Nordisk INC | $123.46 | 2022 | |
| Pfizer INC. | $122.72 | 2023-2025 | |
| Phadia US INC. | $111.60 | 2022 | |
| Grifols USA, LLC | $81.09 | 2023-2025 | Gamunex-C |
| Abbvie INC. | $72.46 | 2024 | |
| Neurelis, INC. | $57.78 | 2023-2025 | Valtoco |
| Genentech USA, INC. | $44.73 | 2025 | Ocrevus Zunovo |
| Amgen INC. | $31.70 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $31.62 | 2025 | Hyqvia |
| Ge Healthcare | $27.82 | 2025 | |
| Merz Pharmaceuticals, LLC | $21.88 | 2025 | Xeomin, Ampyra, Inbrija |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.35 | 2024 | Skyclarys |
| Eisai INC. | $20.12 | 2023 | |
| Amneal Pharmaceuticals LLC | $19.91 | 2024 | Rytary |
| Medtronic, INC. | $19.87 | 2023 | Linq II |
| Lilly USA, LLC | $15.29 | 2024 | Amyvid, Kisunla |
| Aucta Pharmaceuticals, INC. | $14.04 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britta Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.